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Clinical Presentation of 
Myasthenia Gravis
Jianu Catalin, Jianu Silviana 
and Barsan Claudia
Abstract
Despite advances in applied sciences, myasthenia gravis (MG) remains a chal-
lenging disorder to diagnose and treat. The clinical presentation results in either 
transient or persistent painless weakness and abnormal fatigability of any (ocular, 
bulbar, limbs, trunk, respiratory) or all voluntary (skeletal) muscles; however, it 
is usually not to the same extent. Several scoring systems of MG signs or the global 
state of the patient have been proposed in an attempt to provide a standard scheme 
for use by all investigators. Some patients may have non-muscle-related complaints 
due to different disorders which may be associated with MG (thymoma, thyroid 
disorders, other autoimmune diseases, etc.).
Keywords: myasthenia gravis, transient or persistent weakness, skeletal muscles, 
thymoma
1. Myasthenia gravis: overview
Myasthenia gravis (MG) is a neuromuscular autoimmune disease character-
ized by the production of autoantibodies directed against molecules involved in 
neuromuscular transmission (NMT): the α1 subunit of the nicotinic postsynaptic 
acetylcholine receptors (AChR) and muscle-specific tyrosine kinase (MuSK) [1–3].
MG occurs more frequently in women than men; the age of onset in women 
is in their second and third decade of life, while in men, it is in the fourth [1, 4]. 
Moreover, there is a second peak of incidence in the sixth and seventh decades, with 
men being more affected. Epidemiologically, it was found that men tend to experi-
ence more severe symptoms [4, 5].
Clinically, MG is defined by a painless, fluctuant muscle weakness that pro-
gressively increases with repetitive muscle action but decreases with rest [1–3]. 
The degree of weakness is dependent on the exertion of the skeletal muscle group 
involved, but in some cases, it may change over longer periods without any evident 
cause [6].
Even though all types of voluntary muscle can be involved during the disease 
course, MG characteristically begins with a few isolated signs and spreads to other 
muscles within a variable period of time (weeks, months, or even years) [6].
In about 15–20% of the patients, myasthenic symptoms remain confined to the 
ocular muscles; however, with disease progression and usually within 2 years, the 
rest of them develop bulbar symptoms (i.e., dysphagia, dysarthria) and facial, axial, 
and limb weakness [1, 2, 6, 7].
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The maximum severity of MG manifestations is usually reported during the 
first year in two-thirds of patients [1]. Additionally, it has become evident that, in 
general, the illness tends to stabilize, improve (57%), or even resolve (13%) after 
several years [3, 6].
It is important to emphasize that in MG, symptoms may worsen in certain condi-
tions including stress, systemic illness (especially upper respiratory infections), 
hypo−/hyperthyroidism, pregnancy, menstrual cycle, exposure to heat, operative 
procedures, drugs affecting NMT, and fever [1, 5, 8]. However, in the majority of 
cases, no precipitating factor can be found [3, 5]. A severe exacerbation requiring 
endotracheal intubation with mechanical ventilation is defined as myasthenic crisis 
(Class V myasthenia by MG Foundation of America) [5].
The treatment used in MG includes symptomatic treatment (acetylcholinester-
ase inhibitors), rapid short-term immunomodulating therapies (plasmapheresis 
and intravenous immunoglobulin), chronic long-term immunomodulating treat-
ment (glucocorticoids and/or other immunosuppressive agents), and, in selected 
patients, surgical treatment (thymectomy). In all cases, MG management should 
be individualized according to patient characteristics and the severity of the 
disease [3].
Currently, the mortality of MG is extremely low, considering that only among 
the 19% of the patients with severe generalized MG also need endotracheal intuba-
tion; the mortality can reach 8% despite ventilation [5, 6, 9].
2. Clinical features
The cardinal features of the initial course of MG are the transient or persistent 
weakness and abnormal fatigability of skeletal muscles that are typically least severe 
in the morning and after rest and worst as the day progresses and after repetitive 
activities [1, 3, 5] (Table 1).
The weakness, which is mostly asymmetrical, specifically affects the extraocu-
lar, bulbar, and proximal limb or truncal musculature and, in more rare cases, the 
respiratory muscles [3–5].
In about two-thirds of the patients with MG, the presenting symptoms are uni-
lateral or asymmetrical ptosis and/or diplopia due to the involvement of extrinsic 
ocular muscles [2–4].
Over 15% of patients show (as an initial MG symptom) bulbar weakness, 
leading to slurred or nasal speech, voice alterations, or difficulty in chewing or 
swallowing; neck and extremity weaknesses are flagged as complaints in about 5% 
of patients [2, 5, 7, 10].
Importantly, careful questioning frequently reveals evidence of earlier subtle 
myasthenic manifestations, such as repeated purchases of eyeglasses to correct 
blurred vision or avoidance of foods that became difficult to chew or swallow. Also, 
family members may observe a changed, sleepy or sad, facial appearance caused by 
ptosis or facial weakness [1].
It has to be mentioned that, in MG, cognition, coordination, and tendon reflexes 
are normal. Also, local muscle atrophy is rarely seen in myasthenic patients, being 
reported especially in MuSK-antibody MG patients [1, 2, 5, 6].
2.1 Ocular symptoms
Ocular symptoms are the most frequent manifestations of MG, ultimately being 
present in 90% of patients [6]. The major ocular symptoms associated with MG are 
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fluctuating ptosis (often with compensatory wrinkling of the forehead), diplopia, 
and, in milder cases, blurry vision [3, 5]. These manifestations may be intermittent 
in the early stages, typically becoming worse in the evening, while reading or driv-
ing, and especially in bright sunlight [1].
In MG a certain degree of photophobia is seen, commonly worsening the ptosis 
and/or diplopia; as a consequence, some patients often choose to wear dark sun-
glasses [1, 3].
Weakness involving one or more ocular muscles is, by definition, asymmetric, 
fluctuating, and fatigable [1]. The most frequently affected extraocular muscle 
is the medial rectus [3]. Furthermore, in MG, the pattern of weakness cannot be 
correlated with lesions of one or more nerves, and the pupillary responses are 
normal [1].
Asymmetric ptosis of the alternating sides over time is considered pathogno-
monic of MG. In some cases, ptosis can be severe enough to totally occlude vision if 
it is bilateral [1, 3].
Weakness of the orbicularis oculi muscles, frequently seen in MG patients, 
leads to incomplete closure of the eyelids, which produces discomfort by allowing 
soap or water in the eyes during bathing [1, 5]. It should also be mentioned that the 
weakness of lateral and medial recti can determine a pseudo-internuclear oph-
thalmoplegia with limited adduction of one eye and nystagmus of the abducting 
contralateral eye [5].
2.2 Bulbar symptoms
In about 15% of patients [11] with MG, bulbar symptoms, generally mani-
fested as oropharyngeal muscle weakness, are evident from the beginning [12]; 
during the course of the disease, bulbar muscle involvement can be found in 
60% of patients [3]. The characteristic bulbar symptoms seen in MG include 
fatigable chewing (particularly solid food) and swallowing (particularly liquids), 
dysarthria, and inadequate maintenance of the upper airway. Typically, the time 
needed for eating a meal increases, and conversation becomes difficult, especially 
while eating [1, 3, 6].
Level Symptoms Early onset 
<40 years
Late onset 
>40 years
Thymoma
Ocular muscles • Diplopia
• Ptosis
++
++
++
+
+/−
+/−
Bulbar muscles • Articulation
• Face
• Chewing
• Swallowing
• Neck
++
+
+/−
+/−
+/−
+/−
+/−
+/−
+/−
+/−
+/−
+/−
+/−
+/−
+/−
Limbs muscles • -Arms
• -Hands and fingers
• -Legs
+
+
++
+/−
+/−
+/−
+/−
+/−
+/−
Generalized +/− +/− +/− +
Respiration +/− +/− +/− +/−
Table 1. 
Clinical manifestations of myasthenia gravis.
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Dysarthria: Speech difficulties manifesting as dysarthria and nasality are com-
monly seen in MG. Initially, dysarthria is an isolated and fluctuating symptom that 
occurs mostly under the influence of emotions, worsens with prolonged talking, 
and disappears after a “silent period” [6]. Weakness of laryngeal muscles causes 
hoarseness; the voice may become weaker in volume, but MG does not determine 
aphonia [1, 6]. Orbicularis oris weakness is usually observed as the patient becomes 
unable to whistle, to kiss, and to blow up a balloon or by difficulty in pronounc-
ing certain letters (p, f, s). Importantly, vocal cord paralysis, leading to stridor, or 
“crowing” during attempted deep inspirations, may be a sign of severe respiratory 
distress requiring endotracheal intubation [5, 6].
Dysphagia in MG is caused by weakness of the lips, the tongue, the masseter, 
and the pharyngeal muscles or sometimes a combination of these [6]. Dysphagia 
found in MG patients is typically associated with several characteristic signs as 
follows: difficulty chewing caused by incomplete jaw closure resulting from mas-
seter and temporalis muscle weakness; difficulty swallowing exposing the patient to 
a high risk of aspiration, leading to coughing or choking especially while drinking; 
nasal regurgitation of liquids due to palatal muscle weakness; sensation that food 
is sticking in the throat as a consequence of upper pharyngeal muscle weakness; 
and weight loss—which can be correlated with the severity of eating difficulties. 
It is important to emphasize that dysphagia can precipitate a myasthenic crisis in 
patients with MG [1, 5, 6].
2.3 Facial appearance
Myasthenic patients usually have a facial appearance that gives the impression 
of a sleepy, expressionless, or sad person. This particular appearance is caused 
mostly by ptosis and facial weakness. Classical features found in MG are also the 
“myasthenic snarl” and the “rire vertical.” These signs occur as attempting to smile 
produce contraction of the medial part of the upper lip and a horizontal contraction 
of the corners of the mouth with loss of the natural upward curling and thus, gives 
the patient’s smile the appearance of a sneer. The weakness of the facial muscles 
usually occurs insidiously and can be asymmetric. Sometimes, a chronic contracted 
frontalis muscle may give a worried or surprised look to the patient. If weakness is 
severe, the jaw will tend to hang open and determine the patient to actively hold the 
mouth closed by sitting with a hand on the chin for support (studious or attentive 
appearance) [1, 6].
2.4 Limb, trunk, and respiratory weakness
Any trunk or limb muscle may be involved, but some are more often affected 
than are others; thus, neck flexors are weaker than neck extensors, and the deltoids, 
triceps, and extensors of the wrist and fingers and ankle dorsiflexors are usually 
more affected than other limb muscles. MG limb weakness is mostly proximal and 
often asymmetric [1, 5]. In MG the arms are typically more affected than the legs; 
also, in the upper extremities, the extensors are often involved before the flexors, 
while in the lower extremities, the reverse usually occurs [3, 5].
The main complains of the patients with MG which present weakness of the 
limbs or trunk muscles include fatigability, unexplained feelings of heaviness, 
inability to maintain arms at a higher position for a long period of time (i.e., 
when hanging laundry or washing hair), and difficulty in going up and down the 
stairs [6].
In some cases, severe weakness of neck extensor muscles leads to difficulty in 
balancing the head sometimes producing a “dropped head syndrome.” Pain in the 
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back and girdle muscles is frequently reported as a natural consequence of the 
insufficiency of the postural muscles; however, MG is typically not associated with 
chronic pain [1, 3, 5, 6].
Respiratory muscle weakness is revealed by limited chest wall movement and 
manifest use of accessory muscles of respiration. An important diaphragmatic 
weakness leads to orthopnea compromising the respiratory efficiency when the 
patient lies supine [4]. Respiratory muscle weakness may cause life-threatening 
myasthenic crisis with acute respiratory failure requiring immediate intubation, 
mechanical ventilation, and nasogastric tube feeding [3].
Note: MG is more frequently associated with other autoimmune disease than 
the general population. Among the autoimmune conditions found in MG patients 
are hyperthyroidism, rheumatoid arthritis, scleroderma, ulcerative colitis, perni-
cious anemia, Sjogren’s syndrome, and sarcoidosis. Also, autonomic neuropathies, 
inflammatory myopathies, various autoimmune channelopathies, or acquired 
neuromyotonia (Isaac’s syndrome) may be seen in patients with MG especially 
if associated with thymoma. Importantly, in MG patients with tachycardia or 
exophthalmos, a possible hyperthyroidism should always be addressed; it has to be 
mentioned that, in these cases, weakness may persist despite adequate management 
of MG [6, 13].
3. Physical examination
The physical examination should detect fatigable weakness in specific muscle 
groups by repetitive or sustained activity and also again after rest [1, 4].
Diplopia can be demonstrated by having the patient look laterally for about 
30 seconds, leading to evident eye muscle fatigue [3]. The lid ptosis can improve by 
applying cold on the affected eye (“ice pack test”). Also, passively lifting a ptotic 
lid may cause the opposite lid to fall (“enhanced ptosis”) [1]. Cogan’s lid twitch—a 
pathognomic sign in MG—is described as the brief twitch seen in an eyelid that is 
elevated after rest [4, 5].
A useful functional test for dysarthria implies asking the patient to speak aloud 
without interruption producing nasality and/or hoarseness [6].
To test the limb muscle weakness, the patient should be asked to maintain for 
3 minutes a horizontally stretched position of arms, hands, and fingers. In patients 
with MG, this test will lead to shaking or a gradual drooping of arms, hands, or 
fingers. Also, patients should be able to do knee bends or rise from a chair repeat-
edly without any support, 20 times.
Importantly, vital capacity and peak flow measurements should be assessed in 
all myasthenic patients [6].
4. Clinical classification
Several scoring systems of myasthenic signs or the global state of the patient 
have been proposed including the Osserman classification, myasthenia gravis 
composite (MGC) scale, and quantitative myasthenia gravis (QMG) score [6]. 
However, currently the most widely accepted is the MG Foundation of America 
(MGFA) Clinical Classification which divides MG into five main classes and several 
subclasses [3, 5] as follows:
• Class I: Any ocular muscle weakness; may have weakness of eye closure. All 
other muscle strength is normal.
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• Class II: Mild weakness affecting muscles other than ocular muscles; may also 
have ocular muscle weakness of any severity.
 ○ IIa. Predominantly affecting the limb, axial muscles, or both. May also have 
lesser involvement of oropharyngeal muscles.
 ○ IIb. Predominantly affecting the oropharyngeal, respiratory muscles, or both. 
May also have lesser or equal involvement of the limb, axial muscles, or both.
• Class III: Moderate weakness affecting muscles other than ocular muscles; may 
also have ocular muscle weakness of any severity.
 ○ IIIa. Predominantly affecting the limb, axial muscles, or both. May also have 
lesser involvement of oropharyngeal muscles.
 ○ IIIb. Predominantly affecting the oropharyngeal and respiratory muscles or 
both. May also have lesser or equal involvement of the limb, axial muscles, or 
both.
• Class IV: Severe weakness affecting muscles other than ocular muscles; may 
also have ocular muscle weakness of any severity.
 ○ IVa. Predominantly affecting the limb, axial muscles, or both. May also have 
lesser involvement of oropharyngeal muscles.
 ○ IVb. Predominantly affecting oropharyngeal, respiratory muscles, or both. 
May also have lesser or equal involvement of limb, axial muscles, or both.
• Class V: Defined as a state requiring intubation, with or without mechanical 
ventilation, except when employed during routine postoperative management. 
The use of a feeding tube without intubation places the patient in Class IVb [14].
5. Myasthenia gravis subtypes and specific clinical situations
Ocular MG (OMG). Myasthenic weakness that remains restricted to the ocular 
muscles for more than 2 years is defined as OMG [15] (Figure 1). Although most 
patients with OMG also present concomitant weakness of the orbicularis oculi 
muscles, this is not considered as evidence of generalization [5]. Remission may be 
seen in about 20% of these patients; however, it has to be noted that recurrences are 
possible even after 20 years [4, 5].
Generalized MG (GMG) can be further subclassified in early-onset (EOMG) 
and late-onset (LOMG) disease, with the cutoff age usually set at age 40. EOMG 
patients are more often women, typically presenting anti-AChR antibodies and thy-
mus hyperplasia, while LOMG patients are more frequently male and have MuSK 
antibodies in addition to anti-AChR antibodies [1].
MuSK-antibody myasthenia gravis (MuSK-MG). MuSK antibodies have been 
reported in up to 50% of seronegative autoimmune MG cases [16] as well as in 
OMG [17]. MuSK-MG occurs predominately in women from adolescence through 
middle age [1, 5]. The anti-MuSK phenotype has a distinct clinical syndrome with 
prominent weakness in the cranial, bulbar, and respiratory muscles, frequently with 
moderate to severe atrophy of these clinically affected muscles (especially facial 
and genioglossus muscles) [1, 4, 5, 18]. Thus, the major complaints of these patients 
7Clinical Presentation of Myasthenia Gravis
DOI: http://dx.doi.org/10.5772/intechopen.86566
include dyspnea, nasal speech, and dysphagia leading sometimes to an important 
weight loss [2]. Some patients also present weakness of the neck extensor. Typically, 
there is little to no ocular muscle weakness and only a mild involvement of the limb 
muscles. It is important to mention that, in these patients, the myasthenic symptoms 
are more severe than in non-MuSK-MG individuals, with more frequent respiratory 
crises [5]. In MuSK-MG thymic pathology is mostly absent or minimal [19].
Seronegative MG is defined by the absence of both anti-AChR and anti-MuSK 
antibodies (“double-seronegative MG”). These cases are clinically heterogeneous, 
but their frequency is particularly low. It has to be noted that some of these patients 
may have low-affinity anti-AChR antibodies that can only be detected using special-
ized assays [1].
Thymoma-associated MG. Thymic pathology (thymic lymphofollicular 
hyperplasia and thymoma) occurs in 80–90% of MG patients and is typically 
milder in seronegative MG [20]. It was reported that over 10% of patients with 
MG have a thymoma and, conversely, that 35% of thymoma patients have MG [5]. 
Thymoma-associated MG, also termed paraneoplastic MG, is a seropositive MG 
subtype which occurs primarily after the third life decade and is equally frequent 
in males and females. Patients with this MG subtype have a more severe disease 
with lower rates of remission and higher mortality (30%) than patients without 
thymoma [1, 5, 6].
Transient neonatal myasthenia gravis (TNMG) occurs in approximately 15% 
of infants born to mothers with autoimmune MG, as the anti-AChR antibodies get 
transferred across the placenta. The most common symptoms are feeble cry, ptosis, 
facial weakness, difficulty in feeding, respiratory weakness, and, in some cases, 
cyanosis. Rarely, affected infants present arthrogryposis (joint contracture) caus-
ing prolonged immobility in utero. It was found that the symptom severity in the 
newborn is not related to the severity of symptoms in the mother. These myasthenic 
manifestations resolve within the first month of life with acetylcholine esterase 
inhibitors [1, 5].
Juvenile myasthenia gravis (JMG) is defined as the onset of immune-mediated 
MG before age 18 [21] (Figure 2). These patients represent about 15% of the 
Figure 1. 
Ocular myasthenia gravis.
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autoimmune MG cases, being particularly uncommon in the first year of life. JMG is 
rarely associated with thymomas and has a high rate of spontaneous remission [1].
Congenital myasthenic syndromes (CMS) are caused by genetic (mostly 
autosomal recessive) abnormalities of the NMT, leading to fluctuating or persistent 
hypotonia of the ocular, bulbar, or limb muscles; in infancy it may cause arthrogry-
posis, delayed motor milestones, and unexplained apnea episodes. The weakness 
usually worsens during adolescence but then often stabilizes; however, prominent 
myopathy and scoliosis may be present [1, 4].
Lambert-Eaton myasthenic syndrome (LEMS). LEMS is a rare autoimmune 
disorder resulting from impaired release of ACh by the presynaptic terminal of the 
NM junction and in the autonomic ganglia. By definition, LEMS is associated with 
the presence of anti-presynaptic P/Q type voltage-gated calcium channels (VGCC) 
antibodies. Clinically, LEMS has an insidious onset - usually characterized by 
muscle tenderness - followed by progressive development of weakness and fatigue 
[1, 4, 5]. The most frequent symptoms found in LEMS include abnormal fatigue, 
weakness of the proximal muscles (particularly in the legs), hyporeflexia, and, dys-
autonomic manifestations (dry mouth, orthostatic hypotension constipation, and 
impotence). Some patients may present facilitation of strength after brief, isometric 
contraction and decline of strength after sustained activity. LEMS is classically 
associated with underlying malignancy or autoimmune disease. It was reported 
that in about 75% of men and 30% of women, this is a paraneoplastic condition 
accompanying in most of the cases (80%) a small cell lung cancer. The disease can 
also occur with other malignancies such as lymphoproliferative disorders, malig-
nant thymoma, and rarely carcinoma of the breast, stomach, colon, prostate, and 
bladder [4, 5].
Pregnancy. MG may improve, worsen, or remain stable during pregnancy; 
however, a significant risk of deterioration in the puerperium was reported [1, 4]. 
Severe respiratory insufficiency can be triggered by the physical stress of labor and 
delivery; similarly, patients with eclampsia during pregnancy have a higher risk 
of complications of both conditions, considering, for example, that magnesium 
sulfate cannot be used in MG patients [5]. It should also be noted that a newborn 
Figure 2. 
Myasthenic crisis in juvenile myasthenia gravis.
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from a myasthenic pregnancy has a higher risk to develop TNMG (see above). 
Currently, women with MG are advised to delay pregnancy until after the disease 
is stable [1, 4] (Table 2).
Myasthenia gravis 
subtypes and specific 
clinical situations
Notes
Ocular MG • Weakness restricted to the ocular muscles
Generalized MG • Subclassified in early-onset and late-onset MG
• Typically associated with anti-AChR antibodies
MuSK-antibody myasthenia 
gravis
• Prominent weakness in the cranial, bulbar, and respiratory muscles
• Myasthenic symptoms more severe than in non-MuSK-MG patients
Seronegative MG • Rare
• Clinically heterogeneous
Thymoma-associated MG • 80–90% of MG patients also present thymic pathology
• Lower rates of remission and higher mortality
Transient neonatal 
myasthenia gravis
• May occur in infants born to mothers with autoimmune MG
• The myasthenic symptoms resolve within the first month of life with 
treatment
Juvenile myasthenia gravis • The disease onset occurs before age 18
• High rate of spontaneous remission
Congenital myasthenic 
syndromes
• Caused by genetic (mostly autosomal recessive) abnormalities of the 
NMT
Lambert-Eaton myasthenic 
syndrome
• Associated with anti-presynaptic P/Q type VGCC antibodies
• Frequent symptoms: fatigue, weakness of the proximal muscles (par-
ticularly in the legs), hyporeflexia, and dysautonomic manifestations
• Associated with underlying malignancy or other autoimmune disease
Pregnancy • MG may improve, worsen, or remain stable during pregnancy
• Women with MG are advised to delay pregnancy until after the disease 
is stable
Table 2. 
Myasthenia gravis subtypes and specific clinical situations—Summarized features.
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